InVivo in the News

Another patient enrolled in a study by InVivo Therapeutics shows improvement in a treatment for spinal cord injuries

Published: August 19, 2016

(WBZ-AM Boston) Another patient enrolled in a study by InVivo Therapeutics shows improvement in a treatment for spinal cord injuries. The Cambridge company’s Neuro-Spinal Scaffold™ has resulted in improvement now of nearly 63% of patients enrolled in the small INSPIRE trial.

View Article
Boston Business Journal: Shares Soar for BioTech Company InVivo

Published: August 19, 2016

(NECN) Life Sciences Editor Don Seiffert joins necn to discuss the recent increase in shares for BioTech company InVivo.

View Article
InVivo shares soar on good news from study of spine injury treatment

Published: August 17, 2016

(Boston Business Journal) The main trial of a treatment developed by InVivo Therapeutics that could help avoid paralysis in people who suffer acute spinal cord injury now appears likely to hit its main goal, based on news announced Wednesday morning, providing hope that the first-ever product to treat such patients could become available within the next two years.

Shares of Cambridge-based InVivo (Nasdaq: NVIV) were up 21 percent as of 10 a.m. Thursday after news was announced Wednesday morning that the fifth patient in what’s intended as a 20-patient study has been upgraded.

View Article
Bay State Biotech Report: InVivo Reports Success

Published: August 17, 2016

(Bloomberg Radio) InVivo hits a key goal in treating paralysis. That’s on the Bay State Biotech Report, where Bloomberg biotechnology reporter Doni Bloomfield and Boston radio host Anne Mostue discuss the latest in biotech news from the Boston area and across the nation.

View Article
InVivo Hits Key Goal as Fifth Paralyzed Patient Sees Improvement

Published: August 17, 2016

(Bloomberg) InVivo Therapeutics Holdings Corp. announced that the condition of a fifth patient paralyzed by a spinal-cord injury improved after he underwent treatment with its Neuro-Spinal Scaffold, marking a key milestone in the only trial for the experimental device.

View Article
Fifth patient converts in InVivo’s INSPIRE spinal cord injury study; shares up 17% premarket

Published: August 17, 2016

(Seeking Alpha) Conversion Rate to Date is Four Times the Rate in Natural History Databases –
CAMBRIDGE, Mass.–(BUSINESS WIRE)– InVivo Therapeutics Holdings Corp. (NVIV) today announced that the ninth patient implanted with the Neuro-Spinal Scaffold™ in the INSPIRE study has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury in the time between the two- and three-month evaluations.

View Article
Medical study at Vidant offers hope for those with spinal cord injuries

Published: August 11, 2016

(www.witn.com) Vidant Medical Center in Greenville is one of 22 hospitals in the U.S. and Canada selected as a site for a new study focusing on spinal cord injury patients.

Vidant neurosurgeon Dr. Stuart Lee says before this study, doctors would generally just fix the bones in a patient with a bad spinal injury. It really was the only option. But a new study is changing all of that.

View Article
Drs. Stuart Lee, Hilal Kanaan & Domagoj Coric implant 9th & 10th patients with Neuro-Spinal Scaffold

Published: July 12, 2016

(Becker’s Spine Review) Cambridge, Mass.-based InVivo Therapeutics’ INSPIRE study surgeons recently implanted the ninth patient and 10th patient with the Neuro-Spinal Scaffold, according to Street Insider.

View Article
Invivo says FDA approved enrollment of additional patients to allow for 20 evaluable patients in inspire study

Published: July 12, 2016

(Reuters) Invivo therapeutics announces update on the inspire study and fda approval of expansion of the study to 20 evaluable patients. Announced that 9th and 10th patients have been implanted with neuro-spinal scaffold in inspire study

View Article
InVivo’s late-stage study of Neuro-Spinal Scaffold in spinal cord injury progresses; shares up 6% premarket

Published: July 12, 2016

(Seeking Alpha) Thinly traded micro cap InVivo Therapeutics Holdings (NASDAQ:NVIV) is up 6% premarket on light volume in response to its announcement that the 9th and 10th subjects have been implanted in its 20-subject Phase 3 clinical trial, INSPIRE, assessing the Neuro-Spinal Scaffold™ in patients with acute spinal cord injury.

View Article

The articles contained in this section of the website are written and published by persons not affiliated with InVivo. The views expressed in these articles are those of the author(s) and do not reflect the views of InVivo. Additionally, the information contained in these articles may not be current. InVivo disclaims any obligation to correct or to update the information contained in these articles.